171 related articles for article (PubMed ID: 29196028)
21. Single low doses of MPTP decrease tyrosine hydroxylase expression in the absence of overt neuron loss.
Alam G; Edler M; Burchfield S; Richardson JR
Neurotoxicology; 2017 May; 60():99-106. PubMed ID: 28377118
[TBL] [Abstract][Full Text] [Related]
22. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Lee EY; Lee JE; Park JH; Shin IC; Koh HC
Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
[TBL] [Abstract][Full Text] [Related]
23. p38(MAPK)/p53-Mediated Bax induction contributes to neurons degeneration in rotenone-induced cellular and rat models of Parkinson's disease.
Wu F; Wang Z; Gu JH; Ge JB; Liang ZQ; Qin ZH
Neurochem Int; 2013 Sep; 63(3):133-40. PubMed ID: 23714208
[TBL] [Abstract][Full Text] [Related]
24. CNTNAP4 deficiency in dopaminergic neurons initiates parkinsonian phenotypes.
Zhang W; Zhou M; Lu W; Gong J; Gao F; Li Y; Xu X; Lin Y; Zhang X; Ding L; Zhang Z; Li G; Chen X; Sun X; Zhu X; Xu P; Zhang Y
Theranostics; 2020; 10(7):3000-3021. PubMed ID: 32194851
[No Abstract] [Full Text] [Related]
25. Inhibition of Calpain Attenuates Degeneration of Substantia Nigra Neurons in the Rotenone Rat Model of Parkinson's Disease.
Zaman V; Drasites KP; Myatich A; Shams R; Shields DC; Matzelle D; Haque A; Banik NL
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430329
[TBL] [Abstract][Full Text] [Related]
26. MANF protects dopamine neurons and locomotion defects from a human α-synuclein induced Parkinson's disease model in C. elegans by regulating ER stress and autophagy pathways.
Zhang Z; Shen Y; Luo H; Zhang F; Peng D; Jing L; Wu Y; Xia X; Song Y; Li W; Jin L
Exp Neurol; 2018 Oct; 308():59-71. PubMed ID: 29959908
[TBL] [Abstract][Full Text] [Related]
27. Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice.
Inden M; Kitamura Y; Tamaki A; Yanagida T; Shibaike T; Yamamoto A; Takata K; Yasui H; Taira T; Ariga H; Taniguchi T
Neurochem Int; 2009 Dec; 55(8):760-7. PubMed ID: 19647776
[TBL] [Abstract][Full Text] [Related]
28. Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model.
Tapias V; Cannon JR; Greenamyre JT
J Neurosci Res; 2010 Feb; 88(2):420-7. PubMed ID: 19681169
[TBL] [Abstract][Full Text] [Related]
29. Sex Differences in Rotenone Sensitivity Reflect the Male-to-Female Ratio in Human Parkinson's Disease Incidence.
De Miranda BR; Fazzari M; Rocha EM; Castro S; Greenamyre JT
Toxicol Sci; 2019 Jul; 170(1):133-143. PubMed ID: 30907971
[TBL] [Abstract][Full Text] [Related]
30. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures.
Testa CM; Sherer TB; Greenamyre JT
Brain Res Mol Brain Res; 2005 Mar; 134(1):109-18. PubMed ID: 15790535
[TBL] [Abstract][Full Text] [Related]
31. DJ-1 protects dopaminergic neurons against rotenone-induced apoptosis by enhancing ERK-dependent mitophagy.
Gao H; Yang W; Qi Z; Lu L; Duan C; Zhao C; Yang H
J Mol Biol; 2012 Oct; 423(2):232-48. PubMed ID: 22898350
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of endoplasmic reticulum stress is involved in the neuroprotective effects of candesartan cilexitil in the rotenone rat model of Parkinson's disease.
Wu L; Tian YY; Shi JP; Xie W; Shi JQ; Lu J; Zhang YD
Neurosci Lett; 2013 Aug; 548():50-5. PubMed ID: 23774475
[TBL] [Abstract][Full Text] [Related]
33. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
34. Progressive loss of nigrostriatal dopaminergic neurons induced by inflammatory responses to fipronil.
Park JH; Park YS; Koh HC
Toxicol Lett; 2016 Sep; 258():36-45. PubMed ID: 27313094
[TBL] [Abstract][Full Text] [Related]
35. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
[TBL] [Abstract][Full Text] [Related]
36. TNF compromises lysosome acidification and reduces α-synuclein degradation via autophagy in dopaminergic cells.
Wang MX; Cheng XY; Jin M; Cao YL; Yang YP; Wang JD; Li Q; Wang F; Hu LF; Liu CF
Exp Neurol; 2015 Sep; 271():112-21. PubMed ID: 26001614
[TBL] [Abstract][Full Text] [Related]
37. Subcutaneous rotenone rat model of Parkinson's disease: Dose exploration study.
Zhang ZN; Zhang JS; Xiang J; Yu ZH; Zhang W; Cai M; Li XT; Wu T; Li WW; Cai DF
Brain Res; 2017 Jan; 1655():104-113. PubMed ID: 27876560
[TBL] [Abstract][Full Text] [Related]
38. Small molecule TrkB agonist deoxygedunin protects nigrostriatal dopaminergic neurons from 6-OHDA and MPTP induced neurotoxicity in rodents.
Nie S; Xu Y; Chen G; Ma K; Han C; Guo Z; Zhang Z; Ye K; Cao X
Neuropharmacology; 2015 Dec; 99():448-58. PubMed ID: 26282118
[TBL] [Abstract][Full Text] [Related]
39. Puerarin protects dopaminergic neurons in Parkinson's disease models.
Zhang X; Xiong J; Liu S; Wang L; Huang J; Liu L; Yang J; Zhang G; Guo K; Zhang Z; Wu P; Wang D; Lin Z; Xiong N; Wang T
Neuroscience; 2014 Nov; 280():88-98. PubMed ID: 25218963
[TBL] [Abstract][Full Text] [Related]
40. Protective effect of roscovitine against rotenone-induced parkinsonism.
Chen Y; Hou Y; Ge R; Han J; Xu J; Chen J; Wang H
Restor Neurol Neurosci; 2018; 36(5):629-638. PubMed ID: 30056439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
